glp-1 and dual glp-1/gip receptor agonists GIPR/GLP-1R agonist therapies for diabetes weight loss—chemistry, physiology, and clinical applications Mechanisms of action and therapeutic

Digital technologies for delivering multidisciplinary weight-management services: early value assessment

At the present moment, there are currently no FDA approved medications for NASH

Higher costs nationwide Blue Cross Blue Shield associations in Michigan, Massachusetts, New York, Arkansas, Rhode Island and Vermont were all in the red last year, too

Finally, it further promotes the progress of AD (71)

The therapy resulted in a significant reduction in apnea-hypopnea index, substantial weight loss, and lower blood pressure, effects that were consistent across subgroups and robust to sensitivity analyses

Maturity-onset diabetes of the young: what do clinicians need to know